ATC Group: C07AB05 Betaxolol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C07AB05 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C07 Beta blocking agents
3 C07A Beta blocking agents
4 C07AB Beta blocking agents, selective
5 C07AB05 Betaxolol

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 20 mg

Active ingredients in C07AB05

Active Ingredient Description
Betaxolol

Betaxolol is a cardioselective Beta1 receptor blocker which, when applied topically to the eye, lowers intraocular pressure. It is thought to produce this effect by reducing the rate of production of aqueous humour.

Related product monographs

Title Information Source Document Type  
BETAC Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
KERLONE Tablet Web Search MPI, US: SPL/Old

Medicines in this ATC group

Cyprus (CY)

France (FR)

Germany (DE)

Hong Kong (HK)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

Singapore (SG)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.